https://www.thebodypro.com/category/lamivudine-epivir-3tc/tag/croi-conference-on-retroviruses-and-opportunistic-infections
Lamivudine (3TC, Epivir)

CROI (Conference on Retroviruses and Opportunistic Infections)

The Latest

M184V Mutation Associated With Increased Risk of Viral Blip but Not Viral Failure With 3TC-Based Dual Therapy Img

M184V Mutation Associated With Increased Risk of Viral Blip but Not Viral Failure With 3TC-Based Dual Therapy

A retrospective analysis presented at CROI 2018 looked at risk of viral rebound in people who switched to lamivudine (Epivir, 3TC)-based dual antiretroviral therapy.

Promo Image

Long-Acting HIV Treatment: 5 Myths and Realities

Long-acting antiretrovirals: Are they the future of HIV treatment or will the future pass them by? Researcher Charles W. Flexner recently addressed several common myths.